Biological agents for ulcerative colitis: Hypes and hopes

Medicinal Research Reviews

Volumn 28, Issue 2, 2008, Pages 201-218

  Danese, Silvio ^a   Angelucci, Erika ^b   Malesci, Alberto ^a   Caprilli, Renzo ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological agents; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ALICAFORSEN; ALPHA INTERFERON; ALPHA2B INTERFERON; BASILIXIMAB; BETA INTERFERON; BETA1A INTERFERON; CELL ADHESION MOLECULE; CORTICOSTEROID; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 10; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 02; NATALIZUMAB; PLACEBO; PREDNISOLONE; REPIFERMIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ACUTE RESPIRATORY TRACT DISEASE; ANGIODEMA; BASAL CELL CARCINOMA; CLINICAL TRIAL; COLON RESECTION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOOD AND DRUG ADMINISTRATION; HISTOPLASMA PNEUMONIA; HUMAN; INFUSIONAL REACTION; LETHARGY; LEUKOPENIA; LOW BACK PAIN; MONOTHERAPY; MOTOR NEUROPATHY; NONHUMAN; OPTIC NEURITIS; PARESTHESIA; PHOTOSENSITIVITY; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATE CARCINOMA; RECTUM CARCINOMA; REVIEW; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 10; HUMANS; IMMUNOGLOBULIN G; INTERFERONS; INTERLEUKIN-10; MITOGEN-ACTIVATED PROTEIN KINASES; RECOMBINANT FUSION PROTEINS; THIONUCLEOTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39549094473     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20103     Document Type: Review

References (84)

1. Ho TG, Mowat C, Goddard CJR, Fennell JM, Shah NB, Prescott RJ, Satsangi J. Predicting the outcome of severe ulcerative colitis: Development of a novel risk score to aid early selection of patients for second-line medical therapy. Aliment Pharmacol Ther 2004;19:1079-1087.
2. Jarnerot G, Rolny P, Saulbergh-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.
3. Chakravarty BJ. Predictors and, the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993;88:852-855.
4. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.
5. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodhal RI. Early predictors of glucocorticosterid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-835.
6. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, Gendre JP. Predictive factors for outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-279.
7. Edward FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 2002;4:299-315. 2.
8. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
9. Powrie F. T cells in inflammatory bowel disease: Protective and pathogenic roles. Immunity 1995;3:171-174.
10. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev immunol 2003;3:521-533.
11. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F. Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-1178.
12. Fuss IU, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-1270.
13. Plevy S. The immunology of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:77-92.
14. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-1709.
15. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-917.
16. Reinecker HC, Steffen M, Witthoeft T, Dohen C, Pfluger I, Voss A, Raedler. Enhanced secretion of tumor necrosis factor alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-181.
17. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 2004;53:1556-1558.
18. Nakamura S, Ohtani H, Watanabe Y, Fukushima K, Matsumoto T, Kitano A, Kobayashi K, Nagura H. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993;69:77-85.
19. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-1549.
20. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885.
21. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Glodblum R, Despain D, Hogge GS, Rutgeerts P. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group. Evaluation of Natalizumab as continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-1925.
22. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Bin J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-79.
23. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-2381.
24. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7 (suppl 1) S30-S33.
25. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler RB, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-2584.
26. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in steroid-refractory ulcerative colitis: A pilot study. Wien Klin Wochenschr 2001;113:930-933.
27. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti- tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: Result of an open-label study on 13 patients. Dig Liver Dis 2002;34:626-630.
28. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for the treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-634.
29. Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, Bouhnik Y, Dupas JL, Modigliani R, Taillard F, Lemann M. Infliximab for refractory ulcerative colitis or indeterminate colitis:an open-label multicentre study. Aliment Pharmacol Ther 2003;18:175-181.
30. Mamula P, Markowitz JE, Brown KA, Hurd RB, Piccoli DA, Baldassano RN. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2002;34:307-311.
31. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-88.
32. Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003; 52:998-1002.
33. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WSJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
34. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan sH, Hellstrom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-1811.
35. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno de Mesquita M, D'Hoore A, Pennincks F, Rutgeerts P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. Aliment Pharmacol Ther 2004;19:749-754.
36. Lees CW, Shand AG, Penman ID, Arnott ID, Satsangi J. Infliximab is effective as rescue therapy for acute severe ulcerative colitis: The initial Edinburgh experience. Gastroenterology 2006;130 (Suppl II):A656.
37. Walsh A, Cooley R, Templeton D, Florin T, Radford-Smith G. Acute severe ulcerative colitis: A study of predictors of outcome and efficacy for Cyclosporine and Infliximab. Gastroenterology 2006;130 (Suppl II):A84.
38. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476-481.
39. D'Haens G. Infliximab for ulcerative colitis: Finally some answers. Gastroenterology 2005;128:2161-2166.
40. Lawson MM, Thomas AG, Akobeng AK. Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 CD005112.
41. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody C DP571. Aliment Pharmacol Ther 1997;11:1031-1035.
42. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
43. Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, deBeaumont M. Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J Clin Invest 1993;92:372-380.
44. Issekutz T. Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissue by the TA-2 monoclonal antibody. J Immunol 1991;147:4178-4184.
45. Gordon FH, Hamilton ML, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment pharmacol ther 2002;16:699-705.
46. Biogen Idec and Elan announce voluntary suspension of Tysabri® (natalizumab): Elan and Biogen: internet Press Release 2005 (http:/www.elan.com) .
47. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.
48. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
49. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Veerbeck J, Geboes K, Robberecht W, Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362.
50. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to alpha4beta7 integrin. N Engl J Med 2005;352:2499-2507.
51. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55:61-95.
52. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI, An ICAM-1 antisense oligonucleotide prevents and reverse dextran sulphate sodium-induced colitis in mice. J Pharmacol Exp Ther 1997;280:988-1000.
53. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAm-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-1436.
54. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, excalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53:1646-1651.
55. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19:281-286.
56. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-1425.
57. Miner PB, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: A randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006;23:1403-1413.
58. Neurath MF, Becker C, Barbulescu K. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 1998;43:856-860.
59. Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ. RDP Investigators Study Group. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005;11:713-719.
60. Loftberg R, Neurath M, Ost A, Pettersson S. Topical NFkB antisense oligonucleotides in patients with active distal colonic IBD. A randomised controlled pilot trial. Gastroenterology 2002;122:A60.
61. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination of IL-2 and IL-4 reduces glucorticoid receptor-binding affinity and T cell response to glucocorticoid. J Immunol 1993;151:3460-3466.
62. Walker K, Potter J, House A. Interleukin-2 synthesis in the presence of steroids: A model of steroid resistance. Clin Exp Immunol 1987;68:162-167.
63. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003;326:789.
64. Creed TJ, Norman MR, Probert CSJ, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Sheperd NA, Dayan CM, Hearing SD. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18: 65-75.
65. Onrust S, Wiseman L. Basiliximab. Drugs 1999;57:207-213.
66. Creed TJ, Probert CSJ, Norman MN, Moorghen M, Sheperd NA, Hearing SD, Dayan CM. on behalf of the BASBUC investigators. Basiliximab for the treatment of steroid-resistant ulcerative colitis: Further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-1442.
67. Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Asnong K, Maes B, Ceuppens J, Geboes K, Rutgeerts P. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003;98:369-376.
68. Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Daclizumab, a humanized monoclonal antibody to the Interleukin-2 receptor (CD25) for the treatment of moderately to severely active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-ranging trial. Gut 2006 on line.
69. Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 2000;165:6205-6213.
70. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: Past, present and future. Pediatr Transplant 2003;7:19-31.
71. Plevy SE, Salzberg BA, Requeiro M. A humanised anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid refractory ulcerative colitis: Preliminary results of a phase 1 study. Gastroenterology 2003;126:A75.
72. Protein Design Labs reports progress on two humanized antibodies at International Organization of Inflammatory Bowel disease. Internet Press Release, 2004 http://www.pdl.com.
73. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-2095.
74. Schreiber S, Fedorak R, Wild G, Gangl A, Targan S, Jacina M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and tolerance of rhIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 1998;114:A1080.
75. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999;5:44-60.
76. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus Evjr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355-1364.
77. Sinha A, Nightingale J, West KB, Beelanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349:350-357.
78. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602.
79. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-1815.
80. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Kruger S, Cortot A, D'Haens G, Harrer M, Gasche C, Wrba F, Kuhn I, Reinisch W. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728-1733.
81. Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis: An open long-term pilot trial. Aliment Pharmacol Ther 2002;16:1233-1239.
82. Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer D, Mohrle J, Schreiber S. Interferon beta-1a in ulcerative colitis: A placebo controlled, randomised, dose-escalating study. Gut 2003;52:1286-1290.
83. Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, Krakamp B, Malek M, Malchow H, Zavada F, Engelberg Feurle G. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: A randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005;3:581-586.
84. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285.